Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients.

Fiche publication

Date publication

mai 2026

Journal

EClinicalMedicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MANFREDI Sylvain

Tous les auteurs :
Guiu B, Bailly C, Vibert E, Tlili G, Mariano-Goulart D, Edeline J, Touchefeu Y, Durand E, Blanc JF, Chalaye J, Regnault H, Bouvier A, Sergent G, Sengel C, Renaud S, Rode A, Somma C, Chevallier P, Habouzit V, Brenot-Rossi I, Dohan A, Tselikas L, DeBaère T, Manfredi S, Dieudonné A, Fowers K, Boucher E, Patel B, Vicaut E, Garin E,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42023169

Résumé

Selective Internal Radiation Therapy with yttrium-90 (Y90) has been used for decades, yet guideline recommendations remain inconsistent. High-quality real-world data is needed to guide practice. The objectives of this study were to evaluate effectiveness, safety, and patient quality of life (QoL) with TheraSphere™ treatment in real-world clinical practice, and to identify clinical and dosimetric factors associated with survival.